ayment due to Par for the successful completion of the second DIFICID Phase 3 trial. Research and development expense for the fourth quarter of 2011 was $14.0 million, compared to $6.9 million for the fourth quarter of 2010. The increase was related to higher health economics and outcomes research as well as medical affairs expenses, DIFICID life cycle management planning, and preparation for a pediatric clinical trial.
For the fiscal year 2011, Optimer reported net income of $7.8 million, or $0.17 per share on both a basic and diluted basis, as compared to a net loss for the fiscal year of 2010 of $47.3 million, or ($1.25) per share on both a basic and diluted basis.
Net income for the fourth quarter of 2011 was $13.4 million, or $0.29 and $0.28 per share on a basic and diluted basis, respectively, as compared to a net loss for the fourth quarter of 2010 of $11.9 million, or ($0.31) per share, on both a basic and diluted basis.
As of December 31, 2011, Optimer held cash, cash equivalents and short-term investments of $110.6 million and had 46,689,951 shares outstanding.
2012 DIFICID Launch UpdateBetween January 1, 2012 and February 29, 2012, Optimer estimates approximately $11.0 million in DIFICID gross sales, representing 3,931 DIFICID treatments shipped to wholesalers.
Additionally, as of February 29, 2012: Inventory levels at wholesalers remain within the range of 14 to 28 days of demand Approximately 1,400 hospitals had ordered DIFICIDAbout 65% of hospitals covered by Optimer have reordered DIFICIDMore than 600 hospitals are estimated to have placed DIFICID on formulary
Optimer 2011 and Recent Highlights In December 2011, the EMA granted European marketing approval for DIFICLIR™ (fidaxomicin) tablets. In October 2011, Optimer established a Canadian subs
Page: 1 2 3 4 5 6 7 8 Related medicine technology :1
|SOURCE Optimer Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved
. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and FY 2011 Financial Results2
. Optimer Pharmaceuticals to Present at the 32nd Annual Cowen Health Care Conference3
. Optimer Pharmaceuticals Provides Update on DIFICID® (fidaxomicin) Tablets Launch4
. Optimer Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference5
. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)6
. Optimer Pharmaceuticals to Present at BioCentury Newsmakers Conference7
. Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID™8
. Optimer to Provide DIFICID™ Launch Update at Morgan Stanley Global Healthcare Conference9
. Optimer Pharmaceuticals DIFICID Featured in 11 Presentations at 51st ICAAC10
. Optimer Pharmaceuticals to Present at September 2011 Investor Conferences11
. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)